on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with nintedanib and pirfenidone under the National Health Act 1953, section 85 for patients with IPF.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing nintedanib and pirfenidone.
Authority applications
Applying for initial treatment
Apply for initial authority approval to prescribe PBS subsidised nintedanib or pirfenidone to treat IPF in writing and either:
- upload through Health Professional Online Services (HPOS)
- post to PBS Complex Drugs Programs.
All written applications must include completed:
- authority prescription form or forms
- Idiopathic pulmonary fibrosis - initial authority application form.
Applying for a change or recommencement of treatment
Apply to change or recommence PBS subsidised nintedanib or pirfenidone to treat IPF can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment
Apply for continuing authority approval to prescribe PBS subsidised nintedanib or pirfenidone to treat IPF can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for further information.